Centiva Capital’s Aclaris Therapeutics ACRS Stock Holding History

Centiva Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-117,966	Closed	-$130K	–	2082
2024 Q2	$130K	Buy	+117,966	New	+$139K	﹤0.01%	1801

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Centiva Capital's ACRS Position: Q3 2024 in Review

Centiva Capital sold out of Aclaris Therapeutics (ACRS) in Q3 2024, closing a stake of 117,966 shares — an estimated $130K sold.

Centiva Capital first reported a position in ACRS in Q2 2024 and held it in 1 quarter. The position peaked at $130K in Q2 2024. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

Centiva Capital reported no remaining Aclaris Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 117,966 Aclaris Therapeutics shares in Q3 2024, an estimated $130K.
Centiva Capital first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 1 quarter.
Centiva Capital's Aclaris Therapeutics position peaked at $130K in Q2 2024.
81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.